Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Allen Gold sold 12,380 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the completion of the sale, the director directly owned 13,689,166 shares in the company, valued at approximately $482,953,776.48. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Daniel Allen Gold also recently made the following trade(s):
- On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00.
- On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The stock was sold at an average price of $34.00, for a total value of $21,276,622.00.
Roivant Sciences Stock Up 1.9%
NASDAQ:ROIV opened at $35.39 on Wednesday. The stock has a market cap of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13. The business's 50-day moving average price is $29.88 and its two-hundred day moving average price is $27.02. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $35.90.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the previous year, the firm earned ($0.29) earnings per share. On average, equities research analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.
Hedge Funds Weigh In On Roivant Sciences
A number of large investors have recently bought and sold shares of ROIV. Fifth Third Bancorp lifted its position in Roivant Sciences by 8.7% in the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock valued at $130,000 after purchasing an additional 376 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after purchasing an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC grew its holdings in shares of Roivant Sciences by 4.6% in the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after purchasing an additional 445 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock worth $1,891,000 after buying an additional 500 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Roivant Sciences by 1.3% in the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company's stock worth $868,000 after buying an additional 516 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ROIV. TD Cowen increased their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a "buy" rating in a report on Thursday, May 21st. Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Weiss Ratings cut Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, May 22nd. Finally, Guggenheim raised their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, May 26th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $33.59.
Check Out Our Latest Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
